Immunic Current Ratio vs. Return On Equity
| IMUX Stock | USD 1.10 0.01 0.90% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 2.12438837 | Current Value 2.02 | Quarterly Volatility 4.74636152 |
For Immunic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunic utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunic over time as well as its relative position and ranking within its peers.
Immunic |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.91) | Return On Equity (2.16) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immunic Return On Equity vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immunic's current stock value. Our valuation model uses many indicators to compare Immunic value to that of its competitors to determine the firm's financial worth. Immunic is rated below average in current ratio category among its peers. It is rated below average in return on equity category among its peers . At this time, Immunic's Current Ratio is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunic's earnings, one of the primary drivers of an investment's value.Immunic Return On Equity vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Immunic |
| = | 7.53 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Immunic |
| = | -2.16 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Immunic Return On Equity Comparison
Immunic is currently under evaluation in return on equity category among its peers.
Immunic Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immunic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunic will eventually generate negative long term returns. The profitability progress is the general direction of Immunic's change in net profit over the period of time. It can combine multiple indicators of Immunic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 3.8 M | 3.9 M | |
| Operating Income | -99.2 M | -94.3 M | |
| Income Before Tax | -93.6 M | -88.9 M | |
| Total Other Income Expense Net | 5.6 M | 5.9 M | |
| Net Loss | -93.6 M | -88.9 M | |
| Income Tax Expense | 39 M | 40.9 M | |
| Net Loss | -93.6 M | -98.3 M | |
| Non Operating Income Net Other | -827.1 K | -785.7 K | |
| Net Loss | -108.4 M | -102.9 M | |
| Interest Income | 3.1 M | 3.2 M | |
| Net Interest Income | 3.1 M | 3.2 M | |
| Change To Netincome | 52.5 M | 55.1 M | |
| Net Loss | (2.11) | (2.22) | |
| Income Quality | 0.76 | 1.02 | |
| Net Income Per E B T | 1.15 | 0.86 |
Immunic Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immunic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunic's important profitability drivers and their relationship over time.
Use Immunic in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunic will appreciate offsetting losses from the drop in the long position's value.Immunic Pair Trading
Immunic Pair Trading Analysis
The ability to find closely correlated positions to Immunic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunic to buy it.
The correlation of Immunic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immunic position
In addition to having Immunic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Conservative Funds Thematic Idea Now
Conservative Funds
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.